Skip to main content
. 2021 Sep 11;32:102822. doi: 10.1016/j.nicl.2021.102822

Table 1.

Demographics and clinical characteristics of the sample.

PD-ICD PD-noICD HC p
n = 18 n = 17 n = 15
Age 63.33 (8.24) 61.65 (9.21) 61.87 (9.77) 0.837a
Sex, male (%) 16 (88.90%) 14 (82.40%) 14 (93.30%) 0.837b
Education (years) 12.50 [7–20] 11 [7–20] 20 [5–20] 0.319c
Premorbid IQ (WAIS-III Vocabulary) 42.94 (10.13) 44.82 (10.18) 50.2 (7.46) 0.319a
Disease duration (years) 7.13 (3.96) 7.5 (4.52) 0.837d
UPDRS-III 21.50 [10–46] 18.00 [11–30] 0.837e
H&Y stage 2 [1.5–3] 2 [1–3] 0.837b
LEDTOTAL (mg) 970 [450–2660] 792 [250–1664] 0.837e
LEDDA (mg) 194.83 (165.99) 211.76 (144.88) 0.837d
HADS score 6.50 [1–25] 4 [1–10] 6 [1–16] 0.148c
QUIP-RS score 16.50 [7–46] 0 [0–0] >0.001e

Note: Values expressed in Mean (SD) for normally distributed variables, in Median [Range] for other variables. P-values represent FDR-adjusted p-values.

Abbreviations: IQ = Intelligence Quotient; WAIS-III = Wechsler Adult Intelligence Scale-III; UPDRS = Unified Parkinson's Disease Rating Scale; H&Y = Hoehn and Yahr scale; LEDTOTAL = Total levodopa equivalent daily dose was calculated according to the formula described by Tomlinson et al. (2010); LEDDA = Levodopa equivalent daily dose of dopamine agonist was calculated using the same formula; HADS = Hospital Anxiety and Depression Scale; QUIP-RS = Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale.

a

One factor ANOVA.

b

Chi-Square Likelihood Ratio.

c

Kruskall-Wallis.

d

Two-sample T-test.

e

U Mann Whitney.